Proton Pump Inhibitors Worsen Colorectal Cancer Outcomes in Patients Treated with Bevacizumab
Cancers · 02.10.2024 · 16 (19) · 3378
DOI: 10.3390/cancers16193378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 02.10.2024. Verfasst von Chin-Chia Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Colorectal Surgery, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 622, Taiwan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Buddhist Tzu Chi Medical Foundation.
Abstract (Originalsprache)
Background
Approximately one-third of patients with advanced colorectal cancer (CRC) and treated with bevacizumab are prescribed proton pump inhibitors (PPIs) or H2 receptor antagonists (H2RAs). However, there is limited data on the effects of PPIs and H2RAs in these patients. To investigate the oncological outcomes of PPI and H2RA use in CRC patients treated with bevacizumab, we performed a retrospective cohort study using the Taiwan National Health Insurance Research Database and Taiwan Cancer Registry Database from 2005 to 2020.
Methods
In CRC patients treated with bevacizumab, the PPI users and H2RA users were matched with patients without acid-reducing agents (ARAs) by 1:4 propensity score matching. PPI users and H2RA users were matched with propensity scoring in a 1:1 ratio. We divided patients into 4 cumulative PPI dosage levels to assess the dose–response relationship. The primary endpoints were 5-year overall survival and cancer-specific survival.
Results
Compared with ARA non-users, both H2RA users and PPI users were associated with reduced overall survival. PPI users were associated with more significant negative effects on overall survival. Compared with H2RA users, PPI users were associated with lower 5-year overall survival (aHR: 1.19, 95% CI: 1.09–1.31) and cancer-specific survival (aHR: 1.20, 95% CI: 1.09–1.31). A similar dose–response relationship was observed for PPI users in terms of 5-year overall survival and cancer-specific overall survival.
Conclusions
Compared to H2AR use, PPI use was associated with dose-dependent poorer oncological outcomes in metastatic CRC patients treated with bevacizumab.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Colorectal Surgery, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 622, Taiwan.
- School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien 970, Taiwan.
- Division of Colon and Rectal Surgery, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 600, Taiwan.
- School of Medicine, Tzu Chi University, Hualien 970, Taiwan.
- Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 622, Taiwan.
- Department of Medical Research, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 622, Taiwan.
ORCID-Profile: Chin-Chia Wu, Shih-Kai Hung, Yu-Tso Liao, Chuan-Sheng Hung, Jui-Hsiu Tsai
Förderung
- Buddhist Tzu Chi Medical Foundation
Zitieren
APA
Wu, C. C., Fang, C. Y., Chiou, W. Y., Chen, P. T., Hsu, T. W., Hung, S. K., Liao, Y. T., Hung, C. S., & Tsai, J. H. (2024). Proton Pump Inhibitors Worsen Colorectal Cancer Outcomes in Patients Treated with Bevacizumab. Cancers, 16(19), 3378. https://doi.org/10.3390/cancers16193378
Vancouver
Wu CC, Fang CY, Chiou WY, Chen PT, Hsu TW, Hung SK, et al. Proton Pump Inhibitors Worsen Colorectal Cancer Outcomes in Patients Treated with Bevacizumab. Cancers. 2024;16(19):3378. doi:10.3390/cancers16193378
BibTeX
@article{Wu2024,
author = {Wu, Chin-Chia and Fang, Chuan-Yin and Chiou, Wen-Yen and Chen, Pei-Tsen and Hsu, Ta-Wen and Hung, Shih-Kai and Liao, Yu-Tso and Hung, Chuan-Sheng and Tsai, Jui-Hsiu},
title = {Proton Pump Inhibitors Worsen Colorectal Cancer Outcomes in Patients Treated with Bevacizumab},
journal = {Cancers},
year = {2024},
volume = {16},
number = {19},
pages = {3378},
doi = {10.3390/cancers16193378}
}
EUVIMED